Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden hormone danger: common adrenal tumors may raise heart risk

NCT ID NCT04917757

Knowledge-focused Sponsor: Wuerzburg University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at over 3,600 people with adrenal tumors found by chance. Researchers want to see if mild cortisol excess from these tumors is linked to higher risk of death or heart problems like heart attack and stroke. Participants had a simple overnight dexamethasone test to measure cortisol levels and were followed for at least three years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better identify which adrenal tumor patients need treatment to prevent heart issues or early death.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,656 people

The number who actually took part.

Started

Jan 2015

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with adrenal incidentaloma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age ≥18 years * adrenal incidentaloma (≥ 1cm) detected by cross-sectional imaging between January 1, 1996 and December 31, 2015 * imaging characteristics suggestive for an adrenal adenoma or excluded malignancy by follow-up imaging * availability of a 1 mg dexamethasone test result * follow-up data on living status and occurrence of cardiovascular events * follow-up duration of at least 36 months. Exclusion Criteria: * proven pheochromocytoma, primary hyperaldosteronism or adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome * clinical features suggestive for overt Cushing's syndrome; urinary free cortisol (UFC) ≥ 2-fold higher than the upper limit of normal of the local assay * any active malignancy (including adrenocortical cancer) at the time of primary diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal incidentaloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal cortex adenoma Adrenal incidentaloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal incidentaloma

Contacts and locations

Locations

  • University Hospital Würzburg

    Würzburg, 97080, Germany

  • University Turin

    Turin, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.